The Next Wave of Biosimilars: Implications for Adoption and Implementation

Monday, December 12th, 2022 | 11:00 AM - 12:00 PM CT

Since the first biosimilar launched in the U.S. in 2015, the number of approved biosimilars has continued to accelerate in the United States. Competition driven by biosimilars has contributed to decreased drug spending and helped foster a resilient U.S healthcare system. Looking ahead to 2023 and beyond, how can stakeholders promote a competitive landscape that continues to encourage biosimilar uptake? What considerations should payers, pharmacists and pharmacy benefit managers keep in mind as biosimilars expand into new therapeutic areas?​ This webinar will focus on the evolving U.S. marketplace with biosimilars and how stakeholders can work together to sustain a competitive marketplace with biosimilars. Key trends from Amgen’s 2022 Biosimilar Trends Report shaping the biosimilars marketplace will be discussed, as well as the role payers, pharmacists and pharmacy benefit managers play in advancing biosimilar adoption.


Overview of key trends shaping the U.S. marketplace with biosimilars, including recent data on biosimilar uptake, prices, market share and impact on drug spending​. Cost savings for patients, payers and the health system may be supported by biosimilar competition. Insights on how the broader healthcare landscape may shift as biosimilars expand into new therapeutic areas​. The role pharmacists, payers and drug manufacturers play in facilitating biosimilar adoption to help promote a resilient U.S. healthcare system.​



Eugene Rozenblyum - Jake Rodriguez

Eugene Rozenblyum

Director of Trade Relations and Enterprise Drug Solutions, Excellus BlueCross BlueShield

Chelsee Jensen - Jake Rodriguez-1

Chelsee Jensen, PharmD

Senior Pharmacy Specialist and Pharmaceutical Formulary Manager, Supply Chain Management, Mayo Clinic

Billy West - Jake Rodriguez

Billy West, PharmD, MBA

Executive Director and General Manager, National Accounts, Amgen